Status:
WITHDRAWN
Feasibility Trial in Men With Hormone Sensitive Oligometastatic Prostate Cancer
Lead Sponsor:
Dr. Patrick Cheung
Conditions:
Hormone Sensitive Oligometastatic Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
NA
Brief Summary
Patients with hormone sensitive oligometastatic prostate cancer (≤ 5 metastatic tumours outside of regional pelvic nodes with no more than 3 in any organ system) and no previous treatment to prostate ...
Detailed Description
Investigators propose to do a randomized feasibility trial comparing RP vs RT to the prostate in the setting of hormone sensitive oligometastatic prostate cancer. SBRT will be used to treat all of the...
Eligibility Criteria
Inclusion
- Able to provide informed consent.
- Histologic confirmation of prostate adenocarcinoma.
- Stage IV disease with ≤ 5 metastases outside of the pelvis.
- ≤ 3 metastases in any one organ system.
- ECOG performance 0-1.
- All metastatic tumours amenable to SBRT.
- Patient eligible for either RP or RT to the prostate.
Exclusion
- Castration resistant prostate cancer.
- Previous RP or RT to prostate.
- Inability to treat all metastases with SBRT.
- Prior malignancy within the past 5 years, excluding non-melanoma skin cancer, in-situ cancer, superficial bladder cancer, chronic lymphocytic leukemia or low grade lymphoma which is being observed.
Key Trial Info
Start Date :
September 22 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 30 2019
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03301701
Start Date
September 22 2017
End Date
May 30 2019
Last Update
December 1 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N3M5